Entrada Therapeutics (NASDAQ:TRDA) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to outline its pipeline focus on intracellular therapeutics and to preview multiple clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results